Alchemab Targets ‘List Of The Worst-Served Diseases’

Biotech Raises $82m In Series A Financing

In an exclusive interview, Alchemab CEO Alex Leech talks to In Vivo about the company’s method of identifying naturally occurring antibodies to target high unmet needs in oncology, neurodegeneration and infectious diseases.

Target
ALCHEMAB TARGETS HARD-TO-TREAT DISEASES

Alchemab Therapeutics is focusing on protective immune responses associated with individuals who have shown resistance to a disease. It is “looking at nature’s solution to potential diseases,” CEO Alex Leech told In Vivo.

The biotech is identifying “novel and unbiased” therapeutics by evaluating convergent antibody responses using a variety of analytical tools, particularly...

More from Innovation

More from In Vivo